anonymous
Guest
anonymous
Guest
Yes very flawed as the evidence is overwhelming on here of the caliber of reps that were hired due to the scientific process. Filthy,crass and above all a low caliber rep was hired. He can't address why BA over Novartis drug or why there's so many serious adverse events with BA. It isn't a clean drug. Our dream team is full of clunkers who are in over their heads.
And there is more. Evolocumab ( Repatha ) favorable study released.
https://www.cardiovascularbusiness....ogy?utm_source=newsletter&utm_medium=cvb_news